The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Pierre-yves Robert - One of the best experts on this subject based on the ideXlab platform.
-
Effects of subconjunctival bevacizumab on corneal Neovascularization: results of a prospective study
Acta Ophthalmologica, 2012Co-Authors: Y Benayoun, Jean-paul Adenis, Raimondo Forte, Gianluigi Casse, Pierre-yves RobertAbstract:Purpose To evaluate the effect of subconjunctival bevacizumab injections in patients with corneal Neovascularization resulting from different ocular surface disorders. Methods Prospective case series. Fourteen eyes of 13 patients with corneal Neovascularization caused by different ocular surface disorders, such as healed corneal ulcers, long-standing chronic inflammatory diseases and corneal ischaemia secondary to burn were included. All eyes received a single subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphological changes in Neovascularization were evaluated during 3 months using slit-lamp biomicroscopy, corneal digital photography, and computed-assisted semi-automatic analysis of corneal Neovascularization area. Results Recession of corneal vessels was observed in all eyes at 1 week post-injection. The surface of the neovascular tree continued to decrease noticeably for one month and then increased again for the remainder of the follow-up period. The corneal Neovascularization area amounted to 12.14± 4.38% of the corneal surface pre-injection, compared with 9.10± 3.16% post-injection (p=0.02), reflecting a mean decrease in corneal Neovascularization of 25 %. No local or systemic adverse events possibly related to subconjunctival bevacizumab injection were observed. Conclusion Short-term results suggest that subconjunctival bevacizumab can be used safely and effectively for corneal Neovascularization resulting from different ocular surface disorders, providing an additional strategy to improve success of corneal grafts.
-
Effects of subconjunctival bevacizumab on corneal Neovascularization: results of a prospective study.
Cornea, 2012Co-Authors: Y Benayoun, Jean-paul Adenis, Raimondo Forte, Gianluigi Casse, Pierre-yves RobertAbstract:PURPOSE: To evaluate the effect of subconjunctival bevacizumab injections in patients with corneal Neovascularization resulting from different ocular surface disorders. METHODS: Prospective case series. Twelve eyes of 11 patients with corneal Neovascularization caused by different ocular surface disorders, such as healed corneal ulcers, long-standing chronic inflammatory diseases, and corneal ischemia secondary to burn, were included. All eyes received a single subconjunctival injection of 2.5 mg (0.1 mL) of bevacizumab. Morphological changes in Neovascularization were evaluated during 3 months using slit-lamp biomicroscopy, corneal digital photography, and computer-assisted semiautomatic analysis of corneal Neovascularization area. RESULTS: Recession of corneal vessels was observed in all eyes at 1 week postinjection. The surface of the neovascular tree continued to decrease noticeably for 1 month and then increased again for the remainder of the follow-up period. The corneal Neovascularization area amounted to 11.25 ± 4.49% of the corneal surface preinjection, compared with 8.44 ± 3.37% postinjection (P = 0.02), reflecting a mean decrease in corneal Neovascularization of 25%. No local or systemic adverse events possibly related to subconjunctival bevacizumab injection were observed. CONCLUSIONS: Short-term results suggest that subconjunctival bevacizumab can be used safely and effectively for corneal Neovascularization resulting from different ocular surface disorders, providing an additional strategy to improve success of corneal grafts.
Anthony P Adamis - One of the best experts on this subject based on the ideXlab platform.
-
requirement for vascular endothelial growth factor in wound and inflammation related corneal Neovascularization
Investigative Ophthalmology & Visual Science, 1998Co-Authors: S Amano, Richard M Rohan, Masatoshi Kuroki, Michael J Tolentino, Anthony P AdamisAbstract:Purpose Vascular endothelial growth factor (VEGF) is required for vascular development and for ischemia-related tumor, iris, and retinal Neovascularization. The role of VEGF in inflammatory corneal Neovascularization is unknown and was investigated in these studies. Methods A rat model was used in which removal of the corneal and limbal epithelium resulted in circumferential Neovascularization. Corneal VEGF mRNA levels were quantified with ribonuclease protection assays, and VEGF protein was studied in situ using immunohistochemical analysis. Controlled-release pellets containing anti-VEGF antibodies were implanted into the corneal stroma and were used to determine the requirement for VEGF in corneal Neovascularization. Results VEGF mRNA and protein were induced to high levels after corneal injury and were temporally and spatially correlated with inflammation and Neovascularization. VEGF immunoreactivity was localized primarily to the inflammatory cells invading the wounded cornea. The specific inhibition of VEGF bioactivity with neutralizing antibodies potently suppressed corneal Neovascularization. Conclusions These data are the first to demonstrate that VEGF may be required for inflammatory Neovascularization of the rat cornea and to identify VEGF as a functional endogenous corneal angiogenic factor.
Y Benayoun - One of the best experts on this subject based on the ideXlab platform.
-
Effects of subconjunctival bevacizumab on corneal Neovascularization: results of a prospective study
Acta Ophthalmologica, 2012Co-Authors: Y Benayoun, Jean-paul Adenis, Raimondo Forte, Gianluigi Casse, Pierre-yves RobertAbstract:Purpose To evaluate the effect of subconjunctival bevacizumab injections in patients with corneal Neovascularization resulting from different ocular surface disorders. Methods Prospective case series. Fourteen eyes of 13 patients with corneal Neovascularization caused by different ocular surface disorders, such as healed corneal ulcers, long-standing chronic inflammatory diseases and corneal ischaemia secondary to burn were included. All eyes received a single subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphological changes in Neovascularization were evaluated during 3 months using slit-lamp biomicroscopy, corneal digital photography, and computed-assisted semi-automatic analysis of corneal Neovascularization area. Results Recession of corneal vessels was observed in all eyes at 1 week post-injection. The surface of the neovascular tree continued to decrease noticeably for one month and then increased again for the remainder of the follow-up period. The corneal Neovascularization area amounted to 12.14± 4.38% of the corneal surface pre-injection, compared with 9.10± 3.16% post-injection (p=0.02), reflecting a mean decrease in corneal Neovascularization of 25 %. No local or systemic adverse events possibly related to subconjunctival bevacizumab injection were observed. Conclusion Short-term results suggest that subconjunctival bevacizumab can be used safely and effectively for corneal Neovascularization resulting from different ocular surface disorders, providing an additional strategy to improve success of corneal grafts.
-
Effects of subconjunctival bevacizumab on corneal Neovascularization: results of a prospective study.
Cornea, 2012Co-Authors: Y Benayoun, Jean-paul Adenis, Raimondo Forte, Gianluigi Casse, Pierre-yves RobertAbstract:PURPOSE: To evaluate the effect of subconjunctival bevacizumab injections in patients with corneal Neovascularization resulting from different ocular surface disorders. METHODS: Prospective case series. Twelve eyes of 11 patients with corneal Neovascularization caused by different ocular surface disorders, such as healed corneal ulcers, long-standing chronic inflammatory diseases, and corneal ischemia secondary to burn, were included. All eyes received a single subconjunctival injection of 2.5 mg (0.1 mL) of bevacizumab. Morphological changes in Neovascularization were evaluated during 3 months using slit-lamp biomicroscopy, corneal digital photography, and computer-assisted semiautomatic analysis of corneal Neovascularization area. RESULTS: Recession of corneal vessels was observed in all eyes at 1 week postinjection. The surface of the neovascular tree continued to decrease noticeably for 1 month and then increased again for the remainder of the follow-up period. The corneal Neovascularization area amounted to 11.25 ± 4.49% of the corneal surface preinjection, compared with 8.44 ± 3.37% postinjection (P = 0.02), reflecting a mean decrease in corneal Neovascularization of 25%. No local or systemic adverse events possibly related to subconjunctival bevacizumab injection were observed. CONCLUSIONS: Short-term results suggest that subconjunctival bevacizumab can be used safely and effectively for corneal Neovascularization resulting from different ocular surface disorders, providing an additional strategy to improve success of corneal grafts.
S Amano - One of the best experts on this subject based on the ideXlab platform.
-
requirement for vascular endothelial growth factor in wound and inflammation related corneal Neovascularization
Investigative Ophthalmology & Visual Science, 1998Co-Authors: S Amano, Richard M Rohan, Masatoshi Kuroki, Michael J Tolentino, Anthony P AdamisAbstract:Purpose Vascular endothelial growth factor (VEGF) is required for vascular development and for ischemia-related tumor, iris, and retinal Neovascularization. The role of VEGF in inflammatory corneal Neovascularization is unknown and was investigated in these studies. Methods A rat model was used in which removal of the corneal and limbal epithelium resulted in circumferential Neovascularization. Corneal VEGF mRNA levels were quantified with ribonuclease protection assays, and VEGF protein was studied in situ using immunohistochemical analysis. Controlled-release pellets containing anti-VEGF antibodies were implanted into the corneal stroma and were used to determine the requirement for VEGF in corneal Neovascularization. Results VEGF mRNA and protein were induced to high levels after corneal injury and were temporally and spatially correlated with inflammation and Neovascularization. VEGF immunoreactivity was localized primarily to the inflammatory cells invading the wounded cornea. The specific inhibition of VEGF bioactivity with neutralizing antibodies potently suppressed corneal Neovascularization. Conclusions These data are the first to demonstrate that VEGF may be required for inflammatory Neovascularization of the rat cornea and to identify VEGF as a functional endogenous corneal angiogenic factor.
Shoji Kishi - One of the best experts on this subject based on the ideXlab platform.
-
Optical coherence tomographic features of idiopathic submacular choroidal Neovascularization.
American Journal of Ophthalmology, 2000Co-Authors: Tomohiro Iida, Norikazu Hagimura, Taku Sato, Shoji KishiAbstract:Abstract PURPOSE: To clarify the morphologic features of idiopathic submacular choroidal Neovascularization using optical coherence tomography. METHODS: Using optical coherence tomography, we prospectively examined 17 consecutive eyes (17 patients; eight men, nine women; mean age ± SD, 36.0 ± 9.3 years) with idiopathic submacular choroidal Neovascularization. During the follow-up period (mean ± SD, 7.5 ± 3.8 months), we repeated optical coherence tomography in 15 eyes; optical coherence tomography was performed only at the initial examination in two eyes that underwent submacular surgery. RESULTS: Choroidal Neovascularization was observed in the subsensory retinal space anterior to the retinal pigment epithelium as a highly or moderately reflective mass, which protruded from the retinal pigment epithelium in 13 of 17 eyes (protruding type). In four eyes, choroidal Neovascularization was a highly reflective fusiform mass at the level of the retinal pigment epithelium and choriocapillaris (fusiform type). During the follow-up period, choroidal Neovascularization regressed and the protruding mass became a highly reflective fusiform mass in 10 of 11 eyes with the protruding type that underwent repeated examination. In three of the 10 eyes, during 5 to 10 months from initial examination, the choroidal Neovascularization was exacerbated and it again protruded into the subsensory retinal space anterior to the retinal pigment epithelium. Four eyes with the fusiform type remained the same throughout the follow-up period. The overlying retina was thickened and had low reflectivity in all 17 eyes at the initial examination. Optical coherence tomography identified subretinal fluid in only 11 of the 13 eyes with protruding type choroidal Neovascularization. CONCLUSIONS: Optical coherence tomography confirmed subsensory retinal location of idiopathic submacular choroidal Neovascularization anterior to the retinal pigment epithelium. Protruding choroidal Neovascularization transforms to fusiform tissue at the level of the retinal pigment epithelium during the process of regression. Sensory retinal edema was always associated with choroidal Neovascularization.
-
Indocyanine green angiographic features of idiopathic submacular choroidal Neovascularization
American Journal of Ophthalmology, 1998Co-Authors: Tomohiro Iida, Norikazu Hagimura, Shoji Kishi, Koichi ShimizuAbstract:Abstract Purpose: To clarify the indocyanine green angiographic features of idiopathic submacular choroidal Neovascularization. Methods: We performed fluorescein and indocyanine green angiography in 16 eyes of 16 patients (nine men, seven women; mean age ± SD, 35.6 ± 6.9 years; range, 24 to 48 years) with idiopathic submacular choroidal Neovascularization. During the mean follow-up of 11.4 ± 7.9 months (range, 1 to 28 months), angiography was repeated (mean, 2.6 ± 0.5 times; range, 2 to 3 times) in 12 eyes and performed only once in four eyes. Results: In the early phase of indocyanine green angiography, a network of choroidal Neovascularization was observed in 11 of the 16 eyes with well-defined choroidal Neovascularization seen by fluorescein angiography. Choroidal hyperfluorescent areas were noted in 10 of the 16 eyes in the late-phase angiography. Three of the 10 eyes showed focal dilatation of choroidal veins within the hyperfluorescent areas. Choroidal neovascular membrane was located within the hyperfluorescent areas in eight of the 10 eyes with choroidal hyperfluorescent areas. A dark rim surrounding choroidal Neovascularization was observed in 13 of the 16 eyes at the initial examination. Indocyanine green angiography was repeated in nine of the 13 eyes and in the other three eyes without dark rim initially. During the follow-up period, the dark rim became prominent in eight of the nine eyes and developed in one eye without dark rim initially. Choroidal neovascular membrane regressed in these nine eyes. Choroidal Neovascularization remained active or enlarged in three eyes in which the dark rim was stationary or invisible. Conclusions: The dark rim surrounding the choroidal Neovascularization in indocyanine green angiograms appeared to reflect regression of idiopathic choroidal Neovascularization. Choroidal vascular abnormalities such as hyperfluorescent areas or focal venous dilatation seem to be the background lesion predisposing to the choroidal Neovascularization.
